HYQVIA (immune globulin,gamma(IgG) human/hyaluronidase, human recomb)
IMMUNE GLOBULIN, GAMMA (IGG)·AGAMMAGLOBULINEMIA·+6
Takeda Pharmaceuticals America
Indication
Chronic inflammatory demyelinating polyneuropathy
Chronic inflammatory demyelinating polyneuropathy is a rare, immune-mediated neuromuscular disorder affecting the peripheral nervous system and nerve roots. Read more about Chronic inflammatory demyelinating polyneuropathy
10 drugs 10 manufacturers
Drugs that treat it
Common Chronic inflammatory demyelinating polyneuropathy therapies.
Filter & compare in the drug finder →Opens the drug finder with Chronic inflammatory demyelinating polyneuropathy preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonChronic inflammatory demyelinating polyneuropathy is a rare, immune-mediated neuromuscular disorder affecting the peripheral nervous system and nerve roots.
Pathophysiologically, it is driven by an aberrant inflammatory attack on the myelin sheath insulating peripheral nerve fibers, resulting in slowed or disrupted nerve conduction.
Clinically, the condition typically presents across adult populations with progressive or relapsing-remitting symmetric muscle weakness involving both proximal and distal extremities, accompanied by sensory loss, sensory ataxia, and hyporeflexia or areflexia that develops over at least eight weeks.
- nih.gov
Chronic inflammatory demyelinating polyneuropathy is a rare, immune-mediated neuromuscular disorder affecting the peripheral nervous system and nerve roots Clinically, the condition typically presents across adult populations with progressive or relapsing-remitting symmetric muscle weakness involving both proximal and distal extremities, accompanied by sensory loss, sensory ataxia, and hyporeflexia or areflexia that develops over at least eight weeks
- nih.gov
Chronic inflammatory demyelinating polyneuropathy is a rare, immune-mediated neuromuscular disorder affecting the peripheral nervous system and nerve roots Clinically, the condition typically presents across adult populations with progressive or relapsing-remitting symmetric muscle weakness involving both proximal and distal extremities, accompanied by sensory loss, sensory ataxia, and hyporeflexia or areflexia that develops over at least eight weeks
- clevelandclinic.org
Pathophysiologically, it is driven by an aberrant inflammatory attack on the myelin sheath insulating peripheral nerve fibers, resulting in slowed or disrupted nerve conduction
- pennmedicine.org
Pathophysiologically, it is driven by an aberrant inflammatory attack on the myelin sheath insulating peripheral nerve fibers, resulting in slowed or disrupted nerve conduction
- nih.gov
Clinically, the condition typically presents across adult populations with progressive or relapsing-remitting symmetric muscle weakness involving both proximal and distal extremities, accompanied by sensory loss, sensory ataxia, and hyporeflexia or areflexia that develops over at least eight weeks
Personalize your experience
Follow Chronic inflammatory demyelinating polyneuropathy and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.